Videos
Day 1
Fondazione IRCCS Istituto Nazionale dei Tumori
Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study
Istituto Oncologico Veneto
TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
Netherlands Cancer Institute
Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study
Polish Mother’s Memorial Hospital - Research Institute
BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study
Innere Medizin und Onkologie/Hämatologie
Prospective randomised phase-II trial of Ipilimumab/Nivolumab versus standard of care in non-clear cell renal cell cancer – results of the SUNNIFORECAST trial
Netherlands Cancer Institute
First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
Day 2
Karolinska Comprehensive Cancer Center
Survival before and after the Introduction of Adjuvant Treatment in Stage III Melanoma: A Nationwide Registry-Based Study
Melanoma Institute Australia
Primary analysis of the EORTC 1208 Minitub Trial: Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden
MD Anderson Cancer Center
NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study
Istituto Nazionale Tumori Fondazione "G. Pascale"
Phase 1 study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma
Centre François Baclesse
PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
University of Genoa, IRCCS Policlinico San Martino, Genoa & Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy
Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA Program (BIG 14-01) subanalysis
Vanderbilt-Ingram Cancer Center
Final analysis of the phase 3 LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Netherlands Cancer Institute
Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
Hospital 12 de Octubre
Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models. Unveiling novel neuroendocrine subtypes and their clinical implications.
Barts Cancer Institute
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study
Institut Català d´Oncologia
Sitravatinib Plus Tislelizumab for Metastatic Uveal Melanoma with Liver Metastasis: The Open-Label, Multicenter, Phase II GEM-2101 Trial
Day 3
Hospital 12 de Octubre
Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models. Unveiling novel neuroendocrine subtypes and their clinical implications.
Aarhus University
Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial
University of Toyama
JCOG1019: An Open-label, Non-inferiority, Randomised Phase 3 Study Comparing the Effectiveness of Watchful Waiting (WW) and Intravesical Bacillus Calmette-Guérin (BCG) in Patients (Pts) with High-grade pT1 (HGT1) Bladder Cancer with pT0 on the 2nd Transurethral Resection (TUR) Specimen
Poitiers University Hospital
Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial
Gustave Roussy
Unraveling the mechanisms of action and resistance to Trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial
Institut Català d´Oncologia
Multivariable Analysis of Streptozotocin plus 5-Fluorouracil and Everolimus Sequences in Advanced Pancreatic Neuroendocrine Tumor patients: The SEQTOR Trial (GETNE-1206)
University of Pisa
Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO.
Gustave Roussy
Phenotypic and genomic characterization of de novo metastatic prostate cancer: an ancillary study of the PEACE-1 phase 3 trial.
Gustave Roussy
Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial
Fondazione Policlinico Gemelli IRCCS
Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. Preliminary results of the randomized phase 2 TACITO trial.
University of Milan
Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable Stage III NSCLC from the phase 2 DUART trial
Centre Hospitalier de l’Université de Montréal
Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARANOTE trial
Ottawa Hospital Cancer Centre
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small-cell lung cancer (NSCLC)
Institut Curie
Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: results from the randomized phase 2 RELATIVITY-104 study
Humanitas Cancer Center
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Università della Svizzera Italiana
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study
Netherlands Cancer Institute
Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: the NADINA trial
University of California
Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase 3 VOLGA trial
Fudan University
Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): results from DESTINY-Breast06
Humanitas Hospital San Pio X
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Klinik für Dermatologie
Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase 2 ImmunoCobiVem trial
UCSF Health
Phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Gustave Roussy
LBA44
Pembrolizumab vs Ipilimumab in Advanced Melanoma: 10-Year Follow-Up of the Phase 3 KEYNOTE-006 Study
LBA46
Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
Institut Jules Bordet
Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC).
